IL-28R Inhibitors
IL-28R inhibitors constitute a diverse class of compounds that target the IL-28R signaling pathway, primarily affecting the JAK-STAT axis and interconnected pathways. JAK inhibitors such as Baricitinib, Ruxolitinib, and Tofacitinib exert their effects by selectively inhibiting JAK proteins, disrupting the phosphorylation of STAT molecules downstream of IL-28R. This interruption hinders the transduction of IL-28R-mediated signals, leading to the attenuation of cellular responses associated with IL-28R activity.
In addition, broader kinase inhibitors such as Sunitinib, Imatinib, and Dasatinib indirectly modulate IL-28R signaling by targeting tyrosine kinases in pathways interconnected with IL-28R. These inhibitors disrupt downstream signaling cascades, resulting in the attenuation of cellular responses associated with IL-28R. Furthermore, MEK inhibitors like Selumetinib and p38 MAP kinase inhibitors like TAK-715 impact IL-28R signaling by modulating the MAPK pathway. Selumetinib inhibits MEK1/2, affecting downstream events connected to IL-28R activation, while TAK-715 disrupts p38 MAP kinase, influencing interconnected pathways and attenuating IL-28R-mediated cellular responses. This class of IL-28R inhibitors demonstrates a sophisticated approach to modulating the IL-28R pathway, with each compound uniquely targeting specific signaling molecules and pathways, ultimately leading to the attenuation of IL-28R-mediated cellular responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Baricitinib is a Janus kinase (JAK) inhibitor that influences the JAK-STAT signaling pathway. By inhibiting JAK1 and JAK2, it disrupts the downstream signaling cascades involved in IL-28R activation. Specifically, Baricitinib interferes with the phosphorylation events crucial for STAT protein activation, thereby attenuating the transduction of IL-28R-mediated signals and dampening the cellular responses associated with IL-28R activation. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, another JAK inhibitor, disrupts the JAK-STAT signaling axis by selectively inhibiting JAK1 and JAK2. Its impact on IL-28R signaling is indirect but significant, as it modulates the activation of STAT proteins downstream of IL-28R. By impeding the phosphorylation of these STAT molecules, Ruxolitinib hinders their ability to translocate to the nucleus and regulate gene expression, resulting in the attenuation of IL-28R-mediated cellular responses. | ||||||
TG101348 | 936091-26-8 | sc-364740 sc-364740A | 5 mg 25 mg | $207.00 $515.00 | 6 | |
TG101348 (Fedratinib), a JAK2 inhibitor, interferes with the JAK-STAT signaling cascade. Through selective inhibition of JAK2, Fedratinib disrupts the phosphorylation of STAT proteins downstream of IL-28R activation. This disruption impedes the transduction of IL-28R-mediated signals, resulting in the attenuation of cellular responses associated with IL-28R activity. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor that indirectly affects IL-28R signaling. By inhibiting multiple receptor tyrosine kinases, including those involved in pathways intersecting with IL-28R, Sunitinib disrupts the downstream signaling cascades initiated by IL-28R activation. This broad-spectrum inhibition results in the attenuation of cellular responses associated with IL-28R, as the interconnected signaling pathways are modulated by Sunitinib. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that indirectly modulates IL-28R signaling. By inhibiting the activity of certain tyrosine kinases, including those in pathways connected to IL-28R, Imatinib disrupts the downstream signaling cascades initiated by IL-28R activation. This interference leads to the attenuation of cellular responses associated with IL-28R, as the interconnected signaling pathways are influenced by the inhibition of tyrosine kinase activity by Imatinib. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a multi-kinase inhibitor, indirectly influences IL-28R signaling by targeting various tyrosine kinases. Through the inhibition of these kinases, including those connected to IL-28R signaling, Dasatinib disrupts the downstream signaling cascades initiated by IL-28R activation. This broad-spectrum inhibition results in the attenuation of cellular responses associated with IL-28R, as the interconnected signaling pathways are modulated by Dasatinib. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib, a MEK inhibitor, affects the MAPK signaling pathway that intersects with IL-28R signaling. By inhibiting MEK1/2, Selumetinib disrupts the phosphorylation events crucial for the activation of downstream effectors in the MAPK pathway. This interference leads to the attenuation of cellular responses associated with IL-28R, as the MAPK pathway is modulated by Selumetinib, influencing the downstream events connected to IL-28R activation. | ||||||
TAK 715 | 303162-79-0 | sc-362799 sc-362799A | 10 mg 50 mg | $185.00 $781.00 | ||
TAK-715 is a p38 MAP kinase inhibitor that indirectly influences IL-28R signaling. By inhibiting p38 MAP kinase, TAK-715 disrupts the phosphorylation events crucial for the activation of downstream effectors in pathways intersecting with IL-28R. This interference leads to the attenuation of cellular responses associated with IL-28R, as the interconnected signaling pathways are modulated by TAK-715, influencing the downstream events connected to IL-28R activation. | ||||||